Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rheumatologic manifestations of gastrointestinal diseases

J P Katz1, G R Lichtenstein

  • 1Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, USA.

Gastroenterology Clinics of North America
|January 19, 1999
PubMed
Summary

Gastrointestinal diseases can cause rheumatologic disorders, affecting either the intestines or the hepatobiliary system. Understanding these connections is key to treating associated rheumatologic conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology.

The American journal of gastroenterology·2020
Same author

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.

Alimentary pharmacology & therapeutics·2014
Same author

Increased expression of interleukin-8 mRNA in ulcerative colitis and Crohn's disease mucosa and epithelial cells.

Inflammatory bowel diseases·2013
Same author

Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.

Alimentary pharmacology & therapeutics·2012
Same author

Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.

Alimentary pharmacology & therapeutics·2011
Same author

Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.

Alimentary pharmacology & therapeutics·2011

Area of Science:

  • Gastroenterology and Rheumatology
  • Immunology
  • Hepatology

Background:

  • Rheumatologic disorders are significant extraintestinal manifestations of gastrointestinal (GI) diseases.
  • GI diseases with rheumatologic manifestations are categorized into intestinal disorders and hepatobiliary/pancreatic disorders.
  • The underlying causes and mechanisms differ between these two categories.

Purpose of the Study:

  • To delineate the distinct categories of gastrointestinal diseases associated with rheumatologic manifestations.
  • To explain the differing pathomechanisms involved in intestinal versus hepatobiliary/pancreatic GI diseases.
  • To highlight the therapeutic approach targeting the primary GI condition for managing rheumatologic complications.

Main Methods:

  • Review of existing literature on gastrointestinal diseases and their rheumatologic manifestations.

Related Experiment Videos

  • Categorization of diseases based on affected organ system (intestine vs. liver, biliary tree, pancreas).
  • Analysis of pathomechanisms, including immune responses, autoantibodies, and cytokines.

    • Main Results:

    • Intestinal disorders often involve altered intestinal permeability and immune responsiveness.
    • Hepatobiliary and pancreatic disorders typically feature autoantibody production, cytokines, or enzymes.
    • Treatment strategies focus on managing the primary gastrointestinal disease to resolve rheumatologic symptoms.

    Conclusions:

    • Rheumatologic complications are a common extraintestinal feature of GI diseases.
    • Distinct pathophysiological pathways link intestinal and hepatobiliary/pancreatic diseases to rheumatologic conditions.
    • Effective management of rheumatologic manifestations relies on addressing the underlying gastrointestinal pathology.